U.S., May 16 -- ClinicalTrials.gov registry received information related to the study (NCT07591090) titled 'A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer' on May 09.

Brief Summary: This is a Phase II clinical study aimed at evaluating the safety, tolerability, antitumor efficacy, PK and immunogenicity of AK146D1 combined with AK112 in advanced breast cancer.

Study Start Date: June 01

Study Type: INTERVENTIONAL

Condition: Advanced Breast Cancer

Intervention: DRUG: AK146D1 for injection

AK146D1 for injection is an anti-Trop2/Nectin4 bispecific antibody-drug conjugate.

DRUG: AK112 Injection

AK112 Injection is a PD-1/VEGF bispecific antibody.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Akeso

Publishe...